Checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have been shown to have good therapeutic effects in many tumours, leading to significant durable survival, thus a number of these are currently approved for clinical use (Table 1). This evidence concerns the gene CTLA4 and neoplasm.